reason report
bottom line initi op rate
sotp base pt invest thesi four-fold believ
marinu success monet depress franchis
part de-risk clinic trial success marinu
partnership expens doabl go alon
strategi believ emerg epilepsi franchis includ
two probabl three refractori statu epilepticu
pivot program underappreci investor focu
franchis like epilepsi space
increas regulatori commerci
success popul also drive off-label usag
broader popul refractori epilepsi patient posit
biomark appear arbitrag opportun
valuat marinu given
compani similar product shouldnt
ganaxolon work mdd like sage oral even
acknowledg better intern discoveri engin
diversifi pipelin along develop key asset
pg dilig marinu epilepsy/ppd program
catalyst watch includ data phase magnolia studi
part short iv oral top-lin data phase
amarylli studi oral potenti updat next phase
epilepsi program initi data phase
open label feasibl studi refractori statu epilepticu
phase data marigold studi patient
svb leerink proprietari research underscor conclus
proprietari research report includ insight
medacorp physician interview pg sotp analys
compani financi model pg pg respect
pt base sotp analysi forecast cash
flow discount rate risk
invest thesi small number patient phase orphan
epilepsi trial possibl ganaxolon wont succeed larg
pivot trial allopregnanolon biomarker-driven strategi may
success marinu may abl partner program
rais money ramp spend significantli execut
go alon strategi larger better financially-back
compani launch first two product market
slower-than-expect neg clinic develop progress
faster-than-expect loss patent protect assum
link neurosci sector industri report
link initi report
sotp cash flow
discount rate
net debt total capit
year price history/av daili volume mil
compani inform svb leerink llc research
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rx trend deriv im health
initi outperform pt
evolv interest epilepsi stori
tabl content
invest thesi compani
ganaxolon postpartum depress
ganaxolon epilepsi
ganaxolon refractori statu epilepticu
invest thesi
thesi four-fold
believ marinu success monet depress franchis part de-risk clinic
trial success marinu partnership expens doabl go alon
believ emerg epilepsi franchis includ two probabl three refractori
statu epilepticu pivot program underappreci investor focu
like epilepsi space compani genetically-driven biomarker-focus develop strategi
increas regulatori commerci success popul also
drive off-label usag broader popul refractori epilepsi patient posit biomark
appear arbitrag opportun valuat marinu given
compani similar product shouldnt ganaxolon work mdd like sage oral
even acknowledg better intern discoveri engin diversifi
pipelin along develop key asset
pt base sotp analysi forecast cash flow discount rate
although statist signific small number patient phase orphan epilepsi trial
possibl ganaxolon wont success larg pivot trial
allopregnanolon biomarker-driven strategi may success
marinu abl partner program instead rais money ramp spend significantli
execut go alon strategi larger better financially-back compani launch first
two product market
slower-than-expect neg clinic develop progress marinuss clinic program
faster-than-expect loss patent protect assum
compani focus epilepsi neuropsychiatr disord lead compound ganaxolon
found
delawar
timelin key near-term catalyst
ganaxolon compani product candid
act posit alloster modul synapt
extrasynapt gaba-a receptor demonstr anti-
seizur anti-anxieti anti-depress effect
ganaxolon develop differ formul
intraven iv capsul liquid suspens safeti
oral ganaxolon test patient
mg/day
fda grant orphan drug design
ganaxolon sever rare epilepsi type includ
epilepsi refractori statu epilepticu rse
data phase magnolia studi part short iv oral
top-lin data phase amarylli studi oral
potenti updat next phase studi
initi data phase open label feasibl studi
phase data marigold studi
compani focus epilepsi neuropsychiatr disord lead compound ganaxolon
rse refractori statu epilepticu epilepsi caus protocadherin gene
get attent valu given
success drug gaba-
pathway treatment depress
robust sustain treatment efficaci
month phase trial cdd patient
patient support studi
refractori statu epilepsi high-risk high-
preliminari data support use allo-
biomark epilepsi respons support
studi cdd patient
strategi focu orphan epilepsi
indic make sens data
need determin key indic
product non- risk adj revenu stage developmentnon-risk adj npv probabl successrisk-adj npv expect launchrisk-adj net current valu share pipelineganaxolon us defici disord us us refractori statu epilepticu us refractory/allo- posit us postpartum depress royaltiesganaxolon royalti eu defici disord royalti eu royalti eu refractori statu epilepticu royalti eu postpartum depress royalti adj risk-adj risk-adj total asset count fulli dilut includ cap rais risk-adjust equiti valu exclud unalloc account corpor technolog franchis valu howev valu includ net cash adjust marinu pharmaceuticalssotp valuat breakdown product indicationganaxoloneu -cddganaxoloneu -rsenet adjustmentg aadjustmenttotalganaxoloneu -ganaxoloneu -pcdganaxolon us -ref/allo- epilepsyeu royalti epilepsi marinu inc
us rse
us ref/allo-
us
us rse
us ref/allo-
eu rty/mileston
eu rty/mileston
share valu
asset
po use
sotp
us rse
us ref/allo-
us
eu rty/mileston
us rse
us ref/allo-
eu rty/mileston
us cdd
us pcd
us rse
us ref/allo-
us
eu rty/mileston
item shown view sotp valuat
compani report svb leerink est except per share
stock close feb eu royalty/mileston po correspond us
indic po probabl success postpartum depress cdd defici
epilepsi patient posit allopregnanolon biomark rti royalti
stock volatil clinic data news
compani report svb leerink research factset data februari
top-lin data dose optim phase
updat next step
overview key debat
risk
ganaxolon
fda approv
treatment
competit
ganaxolon
approv
think good chanc ganaxolon
pbo effect larger clinic
approv moa gaba-a
modul link valid
similar drug clinic trial via sage
zulresso phase part
result posit show similar treatment effect
sage zulresso
short-iv oral regimen
determin yet
iv dose patient far
think ganaxolon potenti
conveni treatment regimen zulresso drive
share sever moderate-to-sever
name evid loss-of-consci seen
zulresso might result
less restrict rem program zulresso
remain cautious optimist potenti
approv ganaxolon cdd due robust
sustain efficaci phase studi cdd
although patient respect proof-of-
concept data sever rare epilepsi type
extens safety/toler profil oral ganaxolon
patient provid comfort
safeti side henc real focu efficaci
lack late-stag studi data
unclear whether oral
prescrib alon patient
sedation/loss-of-
aris addit larger studi
lack random control
studi data larg human
compani report medacorp physician interview dec svb leerink research
rse refractori statu epilepticu pbo placebo moa mechan action
overview key debat
risk
cautious optimist develop
link -sulfat
biomark fulli valid
lack random control
data larg human studi
earli data possibl
treatment benefit low allo-
sulfat subgroup base
allopregnanolon may
irrelev epilepsi
ganaxolon fail confirm
lack poc data
natur high failur rse
mix patient-specif result
epilepsi
effect
ganaxolon indic mix efficaci
safeti data observ open-label phase
studi despit solid rational gaba-a mechan
popul preliminari evid show
robust treatment benefit low allo-sulf level
subgroup albeit patient
valid
biomark
allow use broader
ganaxolon
approv refractori
believ data though limit support
relationship known neuroprotect
low level link sever
epilepsi type preliminari clinic data post-
hoc analysi ganaxolon cdd
indic greater respons achiev low-allo
subgroup type valid
studi support experiment use
remain cautious optimist indic
efficaci gaba-pathway epilepsi
treatment well establish multipl gaba-
drug wide use differenti
zulresso whose phase trial fail super
refractori statu epilepticu marinu differ
pk/pd profil due modifi dose formul
treat patient earlier line therapi
compani report medacorp physician interview dec svb leerink research
rse refractori statu epilepticu anti-epilepsi drug poc proof concept
ganaxolon gnx neurosteroid synthet analog allopregnanolon
iv oral format treatment rare/refractori epilepsi
what
better treatment regiment short iv oral regimen could significantli reduc in-
hospit time mother seek treatment better safety/toler profil loc seen
patient develop program versu sage zulresso potenti first approv
product sever genetically-driven epilepsi
posit alloster modul gaba-a receptor synapt extrasynapt site
reduct seizur cdd patient
efficaci treatment
exclud day data one subject deem unreli pi
top-lin data magnolia studi part iv oral regimen pbo-control amarylli
studi oral open label phase rse studi on-going preliminari data
phase cdd initi june data expect updat pcd program
ganaxolon nanoparticl composit patent oral form expir year extens
synthesi process patent expir iv patent prosecut grant would expir
forecast us non-risk-adjust sale indic eu royalties/mileston
compani report public svb leerink estim
pcd epilepsi pbo placebo loc loss conscious
scienc behind ganaxolon support clinic develop epilepsi
gabaa modul play critic role disord
gabaa receptor modul demonstr influenc variou disord includ epilepsi
activ extrasynapt gabaa receptor import ambient tonic inhibit vs phasic inhibit synapt site
current gabaa receptor modul benzodiazepin bind synapt receptor lead drug resist
ganaxolon gnx synthet analog allopregnanolon act potent posit alloster
modul synapt extrasynapt gabaa receptor
ganaxolon extrasynapt
affin gabaa receptor
enabl
efficaci potenc
fine tune avoid
high select
summari ganaxolon indic activ develop
year initi
phase oral iv
phase iv recruit phase on-going
compani report public svb leerink research
ganaxolon
depress new mechan creat excit among
physician fda payer lower key hurdl
heavi gener market mani gener ssris/snri patient cycl quickli
good
challeng
fda understand unmet need howev lower hurdl far
gener clear guidanc defin endpoint clinic studi
debat remain accept trial design spcd
tri improv regulatori flexibl understand placebo effect
fast-mov quick access market lead indic
indic expans fda approv allow dtc advertis significantli
mani new novel drug come new mechan appear work
specif excit current drug pipelin gaba nmda
comfort switch multi-drug regimen multipl drug common
want broad label difficult diagnos patient
skeptic paradigm shift class regard prn use
payer forc gener ssri/snri fail treatment
payer pushback howev drug trd easili reimburs
need multipl treatment differ patient respond differ product
svb leerink research world organ data cdc statist medacorp physician interview trd treatment resist depress
snapshot signific unmet need due fda-approv drug
soc ssris/snri take multipl week month onset effect
common biolog complic new mother childbirth
treatment regimen
babi mother low mood
day deliveri recov week
common new mother
around women preval experi us
women moderate-to-sever symptom sever symptom high risk suicid
highli under-diagnos low awar low rate seek treatment result public stigma
distinct window treatment untreat turn mdd
onset typic pregnanc shortli deliveri week last sever month year
self recoveri happen without adequ care may result sever major depress disord
current standard care includ psychotherapi ssris/snri
ssri/snri commonli use mdd work well efficaci time lag ssri/snri
week limit effect mother need rapid treatment whose episod may
shorter mdd patient
fda-approv pharmacolog medicin avail market treatment
compani report public svb leerink research
soc standard care ssri select serotonin re-uptak inhibitor
ganaxolon fda approv treatment
view think rational link gaba modul
similar drug zulresso valid moa clinic trial
moa data suggest allopregnanolon dysregul lead gaba-medi mood disord
rapidli metabol back progesteron limit medic use
concentr rise pregnanc drop deliveri failur adapt abrupt chang
result
antidepress efficaci gaba-modul well document
activ synapt site receptor provid phasic inhibit benzodiazepin barbitur
extrasynapt site receptor enabl ambient tonic inhibit import target gaba
pathway durabl effect without risk drug toler side effect benzodiazepin
clinic evid drug moa sage zulresso shown effect
consist data multipl clinic trial zulresso mdd valid
gaba-pathway approach depress treatment
durabl effect zulresso clinic trial provid confid potenti
clinic efficaci ganaxolon share moa also share structur similar
think ganaxolon could work
scientif literatur show gaba-a modul ganaxolon moa link develop
know moa work therapeut approach demonstr clinic data
ganaxolon share moa structur similar zulresso
compani report public svb leerink research
ganaxolon fda approv treatment
view think ganaxolon phase data part iv
posit show similar treatment effect sage iv zulresso
onset efficaci
durabl effect week
clear dose respons g/kg/h
similar treatment effect zulresso
ganaxolon trial enrol patient similar
sever measur ham-d zulresso trial
show compar chang
ham-d score zulresso
durabl effect
ganaxolon week
similar zulresso
higher dose
ham-d
ham-d week
ham-d treatment
meaning fda novemb zulresso adcom
compani report public svb leerink research
ganaxolon fda approv treatment
view think ganaxolon phase data part iv
posit show similar treatment effect sage iv zulresso
similar zulresso iv ganaxolon show rapid signific antidepress effect
patient effect maintain day note trial head head
ganaxolon iv efficaci line sage zulresso
point ham-d chang sustain day stabl respond remiss rate
compani report public svb leerink research meltzer-brodi et al lancet volume kane et al lancet volume
ganaxolon fda approv treatment
view think ganaxolon favor pk bind affin
profil support use
bind affin pk increment better ganaxolon
ganaxolon strong bind affin may slightli better zulresso
bind affin combin favor pk data profil support potenti effect
compani report public svb leerink research
ganaxolon competit vs sage iv zulresso
view think ganaxolon differenti conveni iv
oral regimen better safeti vs zulresso may enabl less strict rem
ganaxolon differenti
still risk
short simpl iv oral regimen
short-iv oral regimen still optim
iv burden shorter infus reduc in-hospit
time could facilit outpati treatment option
titrat step need infus bag
requir contrast sage iv bag zulresso
oral dose increas conveni would like
appeal moder patient
although oral test
product less sever yet oral dose
regimen still defin
dose oral administr disclos yet
dose optim complet
await data final short-iv oral dose
regimen valid consist efficaci result
better safeti profil
minim patient data iv
bioavail may low
common report somnol
dizzi prior trial
loc syncop observ even highest
dose consist previou data patient
contrast zulresso dose patient
clear risk loc fda highlight
major concern novemb fda adcom
studi power small patient
arm
oral bioavail food per
human data higher due
modif
think short iv oral regimen combin better safeti profil vs zulresso could enabl less strict
rem program drive usag sever moderate-to-sever popul
compani report public svb leerink estim
rem risk evalu mitig strategi advers event
ganaxolon competit vs sage iv zulresso
view believ high unmet need market room sever
product ganaxolon could benefit sage market educ effort
ganaxolon could fda-approv product
zulresso could first
fda-approv
expect launch
strong efficaci rapid
onset zulresso
facilit educ
patient identif
process treatment
could
second fda approv
complementari
ganaxolon could
approv
second product
could
awar physician
comfort level new moa
ganaxolon like
place
possibl launch
could help expand
base diseas profil
prefer patient doctor
could choos iv
zulresso oral
ideal patient
option in-pati hospit
set altern site care
anticip sage launch zulresso educ expand address market
believ physician like tri product choos tailor treatment per patient
compani report svb leerink research fda adcom
view final data two on-going trial help support
oral efficaci dual short-iv oral combin valid strategi
demonstr far
iv effect
onset action
data wait
durabl effect month stop iv
baselin score
multipl efficaci scale consist
dose explor shorter iv follow oral
iv shown loc syncop
preliminari data though limit oral
suggest similar treatment signal
patient week dose
baselin score
primari endpoint chang baselin
top-lin data expect
goal safeti efficaci pk data oral
efficaci data mean reduct day
baselin score
day
dose ascend dose regimen oral
primari endpoint chang baselin
top-lin data expect
believ iv data sage clinic data demonstr iv ganaxolon effect
earli data suggest oral effect cautious optimist amarylli trial read
need final iv oral combo data valid marinuss strategi conveni iv oral regimen
compani report svb leerink research fda adcom
view believ ganaxolon place like
nich product non-risk-adjust sale us
postpartum depress
ganaxolon
treat
none treat
forecast us non-risk-adjust sale
ganaxolon
use gross price iv oral
sale estim base manag
discuss medacorp kol call
compani report svb leerink estim medacorp physician interview
ganaxolon
epilepsi favorit neurosci market across key theme
good
challeng
less patient seizur free drug
patient dont respond current drug treatment resist
signific off-label use creat great opportun new agent
posit bia market want new drug approv
guidanc well-defin endpoint clinic studi
regulatori flexibl understand differ patient respond differ product
mover biopharma compani smart develop strategi
focus lead indic orphan epilepsi nich
result lower develop cost speed market
mani new novel drug come new mechan appear work
reformul also ad valu
efficaci drug-drug interact
comfort frequent switch
comfort prescrib multipl drug patient
rel low payer pushback price power reimburs
understand need pay multipl treatment
mani patient respond current drug seizur
move past gener easi physician easili label patient refract
svb leerink research compani report medacorp physician interview cdc statist us epilepsi foundat
histori epilepsi develop ganaxolon oral long track record
recent marinu shift focu rare epilepsi strong treatment signal
pediatr w/ histori
studi
mg/kg/day
mg/kg/day
mg/kg/day
mg/kg/day
complet respons
complet
respons
ole part
liquid
mg/day
mg/day
chang vs despit
fail meet signific cgi-i
patient improv median
reduct
median reduct improv
month month
primari endpoint seizur reduct except fragil measur cgi-i
cgi-i clinic global impress improv ole open label extens studi
compani report press releas svb leerink research poster
histori epilepsi develop efficaci signal observ phase trial
open label studi drug-resist adult focal onset seizur
phase adjunct treatment efficaci shown seizur reduct respond rate
open label studi sustain effect seizur frequenc respond rate reduct
sustain week
rate week
ganaxolon hit primari endpoint mean reduct seizur frequenc adjunct treatment
adult focal onset seizur support phase studi focal onset seizur
safeti expect condit includ dizzi fatigu sleepi
compani report press releas svb leerink research
histori epilepsi develop achiev statist signific
phase adult refractori focal onset seizur despit treatment effect
clinic design phase refractori focal onset seizur
reduct seizur
goal efficaci safeti ganaxolon adjunct therapi
patient site global concomit
dose mg/day week
primari endpoint median reduct seizur frequenc
neg data fail meet
treatment effect pbo observ
marinu suspend focal onset seizur program due fail phase clear reason could
identifi instead compani shift focu statu epilepticu pediatr orphan epilepsi disord
compani report press releas poster svb leerink research
ganaxolon approv cdd
view despit failur focal onset think shift orphan epilepsi
promis strategi earli data look robust
marinu explor rang pediatr epilepsi behavior condit
select futur studi
select futur studi
lead epilepsi
indic on-going phase
epilepsi would next
prioriti potenti updat later
next phase develop
like compani strategi focus rare orphan epilepsi
focal onset epilepsi consist highli heterogen patient studi variabl differ geographi
wherea genet type rare/orphan epilepsi offer homogen well-defin popul studi
ganaxalon anti-seizur activ could greater treatment signal homogen popul
genet screen tool identifi rare/orphan epilepsi patient avail increasingli use today
preced biotech strategi gw gwph op epidiolex fda approv
compani report press releas svb leerink research
ganaxolon approv cdd
view cdd fda approv medic date ganaxolon
shown robust sustain efficaci open label phase studi
gene role cytoplasm
nucleu impact neuron connect
effect
protein
defici disord cdd caus
mutat cyclin-depend kinase-lik
gene locat chromosom
early-onset treatment-refractori seizur
common cdd patient combin
sever neuro-development impair
walk talk feed well gi
respiratori sleep issu
current antiepilept drug limit
efficaci short-liv benefit seizur
burden cdd patient current
approv therapi cdd treatment caus
high unmet need cdd fda support new agent space
provid guidanc marinu appropri design larg phase trial
ganaxolon also grant orphan drug design fda cdd treatment
compani report press releas svb leerink research ila genet commiss blog nation organ disord nord
ganaxolon approv cdd
view cdd fda approv medic date ganaxolon
shown robust sustain efficaci phase studi
phase clinic design cdd
summari phase patient detail result
patient age confirm
dose mg/day month
follow ole studi
primari endpoint median reduct
secondari chang seizure-
free day per cgi-i
clinician parent/caregiv
summari efficaci
median reduct seizur frequenc
median increas seizure-fre day
patient improv
median reduct seizur frequenc
year open label respond
median reduct seizur frequenc
phase studi cdd patient show robust efficaci seizur reduct patient
open label extens patient complet main trial first show long-term sustain efficaci
compani report press releas svb leerink research poster dec
ganaxolon approv cdd
view cdd fda approv medic date ganaxolon
shown robust sustain efficaci phase studi
seizur reduct seen patient
patient highli non-
durabl least stabl seizur reduct
patient month
durabl respons
month
subject stabl
mild increas
exclud day data
one subject deem
unreli pi
patient experienc clear
improv seizur frequenc
reduct seizur frequenc increas extens studi
ganaxolon gener safe well toler
report somnol frequent report ae prior ganaxolon trial
discontinu due seriou advers event patient discontinu prior complet
treatment due lack efficaci
note subject ole data
total time abstract submiss
ganaxolon approv cdd
view final data phase cdd studi valid ganaxolon
potenti epilepsi treatment
demonstr far
oral ganaxolon demonstr efficaci cdd
robust seizur reduct patient albeit small patient number
extens period month show stabl improv seizur reduct patient
oral shown seriou advers event report somnol
extens safeti data exist oral test patient seriou safeti issu
data wait
primari endpoint reduct seizur
baselin
phase week titrat follow long-term open-label phase
data expect
patient confirm mutat early-onset refractori
believ oral data ganaxolon cdd promis suggest effect phase trial
need final phase cdd data valid ganaxolon epilepsi treatment still risk
move forward epilepsi given fail phase focal epilepsi show strong signal
phase
compani report svb leerink research fda adcom
ganaxolon confirm treatment effect epilepsi
view epilepsi recent describ report
increas awar epilepsi commun
genet research demonstr gene
mutat lead early-onset drug-resist epilepsi
mutat gene locat
 chromosom lead multipl difficult-
to-treat seizur mostli affect femal
earli onset month
patient also mild-to-sever
cognit disabl psychiatr
approv treatment epilepsi
patient dravet-lik symptom
 drug valproat clobazam
stiripentol prescrib efficaci
benzodiazepin use rescu
like cdd high unmet need physician eager therapi option
ganaxolon also grant orphan drug design fda epilepsi treatment
compani present report svb leerink research allianc plo genet
ganaxolon confirm treatment effect epilepsi
view cautious optimist think treatment signal
data mix ganaxolon open-label flexible-dos phase studi
patient level data phase studi
design phase studi
seizur
reduct
dose flexibl dose mg/day
capsul mg/kg/day liquid
suspens open label
period follow extens
seizur frequenc
secondari chang
clinician parent/caregiv
treatment effect observ
efficaci safeti appear mix
patient seizur reduct
inconsist cgi data
level improv exactli
case rash consid
patient discontinu due
discontinu due lack efficaci
believ phase data show ganaxolon effect seizur reduct howev mix result make
us cautiou data produc
median seizur reduct show benefit line current use
valid biomark allow use broader refractori epilepsi
view research albeit limit suggest connect low
level variou type epilepsi support biomark approach
report low level
subject
lower level measur
method
adapt tan et al elisa enzyme-link immunosorb assay
level measur cdd significantli lower vs healthi control
patient show reduc level neurosteroid includ
healthi kid
lower observ
major cdd patient
compani report press releas svb leerink research poster dec tan et al human molecular genet marina epilepsia
valid biomark allow use broader refractori epilepsi
view research albeit limit suggest connect low
level variou type epilepsi support biomark approach
level also link statu epilepticu support use biomark
lower level
csf serum
known neuroprotect low level link seizur suscept epilepsi model
level report sever epilepsi type statu catameni stress-induc tempor lobe
need see allo-biomark data epilepsi type valid connect util predict
biomark level may relev broader rang epilepsi type
biomark valid ganaxolon show superior vs benzos/a statu epilepticu low level
proport refractori epilepsi patient low level make elig treatment ganaxolon
compani report svb leerink research poster dec stefano et al epilepsia reddi jasper basic mechan epilepsi giusepp
valid biomark allow use broader refractori epilepsi
view level connect elev treatment effect
cdd studi help support case biomark
respond analysi phase data
respond reduct seizur frequenc
subgroup analysi patient low vs high allo-
divis also align respond vs non-respond
patient
respond got
chart scale
respond
high allo- defin
allo- defin
retrospect analysi biomark allo-
median chang seizur rate
significantli improv
post-hoc analysi studi point robust treatment effect low allo- subgroup
patient subdivid low vs high allo- signific treatment respons observ
low allo- patient group help support case allo- could predict biomark respons
valid biomark allow use broader refractori epilepsi
view level connect elev treatment effect
cdd studi help support case biomark
clinic data cdd studi point correl treatment effect level
retrospect analysi patient
retrospect analysi cdd patient
patient high
high level
substanti treatment effect
biomark subgroup
substanti treatment effect
biomark subgroup cdd
substanti treatment effect observ biomark low level subgroup cdd
substanti seizur reduct studi support potenti use predict biomark
broad rang epilepsi
compani report press releas svb leerink research poster dec
valid biomark allow use broader refractori epilepsi
our view favor safeti profil support potenti off-label use broad
rang epilepsi patient target biomark
extens databas safety/toler oral ganaxolon
sedat common
safeti profil oral ganaxolon patient
iv ganaxolon test patient
somnol common advers event oral
ganaxolon safeti profil line current
somnol uncommon
deterr usag among physician
believ extens safeti profil patient appreci treat physician
concern read sage zulresso allevi fact loc syncop
seen iv formul ganaxolon despit test patient
favor ddi data support greater off-label use physician epilepsi must titrat
constantli avoid mitig ddi today
diagnosi rate newli character rare epilepsi
syndrom believ diagnosi rate low date increas
recent fulli defin distinct orphan epilepsi disord
mutat initi thought specif associ hanefeld variant rett syndrom
earli onset seizur promin featur addit research indic distinct rett
similarli previous diagnos epilepsi type advent genet map allow
research isol gene lead caus rare type epilepsi
gene ad standard epilepsi genet screen panel scan
multipl marker rang epilepsi drive diagnosi rate significantli
standard epilepsi genet screen panel scan specifi gene scope link variou epilepsi
disord facilit diagnosi treatment epilepsi exampl genedx
gene recogn intern leagu epilepsi ila ad
multipl genet panel believ children epilepsi increasingli identifi
patient advocaci group establish disord inform educ
effort grow believ patient found faster rate
gene test includ comprehens epilepsi panel subpanel
anticip increas diagnosi rate time cdd epilepsi
compani report press releas svb leerink research nation organ disord blueshield medic polici manual genedx epilepsi panel
believ ganaxolon us non-risk-adjust sale
cdd
forecast us non-risk-adjust sale
ganaxolon cdd
use gross price
assum gross-to-net
assum diagnosi rate cdd
gradual ramp
respect
cdd epilepsi
pediatr
pediatr
patient treat
patient treat
compani report svb leerink estim medacorp physician interview
ganaxolon
ganaxolon approv refractori statu epilepticu
refractori statu epilepticu treatment
statu epilepsi sever fatal diseas affect peopl us
se patient hospit treat intraven antiepilept drug benzodiazepin util
patient min continu seizur fail line treatment character refractori
rse patient medic induc coma via anesthet effort reduc brain activ halt seizur
patient wean anesthesia typic within hour
seizur continu resum upon wean anesthesia hour patient character super
current medic indic se seriou rse srse condit
accompani complex complic high mortal
import distinct rse srse srse patient extrem sever must
go anesthet halt seizur anesthet caus patient lose gaba receptor
thu becom less respons gaba agent could sage drug fail srse sinc
marinu target line therapi anesthesia marinu may issu
compani report press releas svb leerink research epilepsia
ganaxolon approv refractori statu epilepticu
view mechanist rational ganaxolon gaba target
agent substanti effect refractori statu epilepticu
moa gaba agent known work
gaba pathway involv statu epilepticu
multipl gaba-drug wide use
benzodiazepin pam gaba wide util first-lin soc treatment statu epilepsi
efficaci benzodiazepin limit respond due drug toler synapt gaba-a receptor
strong affin synapt ambient inhibit extrasynapt tonic inhibit site gaba-a receptor
extrasynapt receptor intern therefor provid durabl enhanc effect rse treatment
demonstr activ least compar preclin rat model benzodiazepine-resist se
preclin rat model benzodiazepin refractori se show anti-epilept synergi combin ganaxolon
diazepam block pilocarpine-induc seizur rat
anti-seizur effect observ previou studi multipl seizur type despit mix result
clinic evid ganaxolon show effect anim model statu epilepticu
iv pharmacokinet brain penetr preclin rat model
ganaxolon allopregnanolon
administ iv rat model
paramet higher brain
combin longer half life
slower clearanc ganaxolon better
posit durabl treatment effect
rse vs agent
compani report press releas rogawski et al epilepsia svb leerink research
ganaxolon approv refractori statu epilepticu
view sage zulresso fail phase srse
major read ganaxolon target earlier stage diseas
sage zulresso demonstr treatment efficaci srse patient despit failur phase studi
neg phase studi ever random control trial srse neg result
global studi patient site
primari endpoint continu resolut se follow wean
zulresso phase data srse
zulresso emerg use srse
ga wean respons dose
wean respons data zulresso support potenti treatment effect pam gaba-a receptor
believ ganaxolon target earlier less-sever stage statu epilepticu still
potenti substanti treatment effect phase
compani report press releas svb leerink research
ganaxolon approv refractori statu epilepticu
view marinu strategi refractori statu epilepsi treatment make sens
go line use somewhat de-risk compar sage approach
acut treatment iv
marinu strategi similar moa differenti pk/pd improv dosing/administration/formul
well earlier line therapi use vs sage product
compani report press releas svb leerink research
believ ganaxolon us non-risk-adjust sale
rse
forecast us non-risk-adjust sale
ganaxolon rse
use gross price
rse
sale estim base manag discuss
medacorp kol call
ganaxolon
compani report svb leerink estim medacorp physician interview
physician feedback discuss american epilepsi societi
confer medacorp call
ganaxolon interest
neurosteroid
one kol highlight ganaxolon asset watch neurosteroid
would new type drug epilepsi
physician intrigu fact ganaxolon explor statu
epilepticu high focu doctor patient new
agent indic
data present show promis compani focus
epilepsi biomark respons data could certainli improv
physician approach treat patient type rare genet epilepsi
level epilepsi
intrigu need
data
physician excit potenti biomark predict respons
epilept medic treatment regimen current trial-and-error tailor
per patient see ganaxolon potenti agent benefit
intrigu marinu data physician cautiou think data
far patient enough confirm biomark theori yet
sever key theme
epilepsi
multipl physician emphas key theme confer
excit new mechan
grow focu orphan diseas dravet lg tuber sclerosi
search biomark epilepsi acceler
genet test becom widespread standard
discuss medacorp physician dec discuss physician attend dec svb leerink research
physician feedback discuss american epilepsi societi
confer medacorp call
similar dravet lg
level intract
seizur fewer
payer pushback
screen test could
one physician larg epilepsi center excel indic patient
see much fewer dravet lg patient
howev physician confirm level intract seizur sever
less respons current compar condit
one physician indic unabl order epilepsi genet screen
panel one third time request patient due lack
payer coverag patient afford cost pocket
physician seen slight decreas genet screen cost enough
yet indic payer coverag would chang
valuabl epilepsi
field gaba moa
preced
physician believ moa clinic toolbox use treat
highli refractori patient run avail need option
physician understand gaba pathway work epilepsi
use benzodiazepin statu epilepticu gener epilepsi
thu see ganaxolon moa rational approach
ganaxolon still
failur srse
one physician indic go sever statu epilepticu
patient difficult patient stage tend
satur gaba receptor could reason sage trial fail
given ganaxolon target earlier line therapi diseas
progress physician believ still possibl get treatment effect
discuss medacorp physician dec discuss physician attend dec svb leerink research
physician feedback discuss american epilepsi societi
confer medacorp call
physician focus
replic efficaci
safeti less question
physician believ replic efficaci seen phase
trial phase studi would compel motiv tri
physician indic safeti profil appear favor given ganaxolon
dose patient alreadi thu question turn efficaci
durabl effect
epidiolex fintepla
sizeabl number
refractori patient
one physician indic launch epidiolex dravet lg
potenti launch fintepla dravet could mean sizeabl number intract
epilepsi patient becom better control thu partli minim need
new moa agent like ganaxolon
said physician suspect epilepsi patient respond singl
agent ganaxolon still abl captur share patient
new agent statu
epilepticu
physician univers agre new agent differenti moa need
treat statu epilepticu especi keep patient go forc coma
lead perman brain damag period time long
discuss medacorp physician dec discuss physician attend dec svb leerink research
led season manag team
previous serv presid ceo two privat biotech compani
messag pharmaceut
forti year execut manag experi drug develop includ year
smithklin beecham acquir glaxo
hold econom purdu univers busi manag
univers minnesota
year execut financ oper leadership experi biotechnolog compani
previous serv cfo polymedix execut director financ
hold busi administr univers hartford licens
year experi build expand pipelin biopharmaceut industri
previous serv chief medic offic invivo therapeut held role cubist
pharmaceut chiron
hold medic degre univers california davi also complet
resid neurolog
year transact commerci experi life scienc health care industri
previous held sever posit fidem capit cempra
pharmaceut cephalon
hold busi administr market boston colleg financ
entrepreneurship babson colleg
 oper activitiesnet compens premium market debt issuanc costs/debt oper asset use oper invest activitieschang market use invest financ activitieschang proce common use financ equival begin equival end compani report svb leerink llc estim marinu inc
 balanc sheet asset expens current stockhold equitycurr liabilitiesaccount payable/accu portion current equitycommon paid-in comprehens stockhold liabil stockhold compani report svb leerink llc estim marinu inc
